Non Executive Director appointment and retirement
31 Aug 2022
Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr David Petrie, has accepted an invitation to join the Board of Mayne Pharma, effective 1 September 2022.
Mayne Pharma 2022 Full Year Results Media Release
26 Aug 2022
Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, we reported annual revenue growth for the first time in five years. Excluding retail generics, the remaining businesses which represent more than 80% of reported gross profit grew 27% on the prior corresponding period (pcp).
Mayne Pharma CEO announces plan to retire
19 Aug 2022
Mayne Pharma Group Limited advises that Chief Executive Officer (CEO) Scott Richards has announced his intention to retire following a decision by the Board to relocate the CEO role to the US on a permanent basis. Mr Richards is unable to make this commitment and wants to return to Australia for personal reasons.
Mayne Pharma announces sale of Metrics Contract Services
10 Aug 2022
Mayne Pharma today announced that it has entered into an agreement with Catalent to sell Metrics Contract Services for a total cash consideration of US$475 million (~A$679 million)
Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring
8 Aug 2022
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring
NEXTSTELLIS® oral contraceptive nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent
2 Aug 2022
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent.
Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS®
29 Jul 2022
Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
NEXTSTELLIS® oral contraceptive now available in Australia
26 Jul 2022
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets), a first-of-its kind oral contraceptive with a novel estrogen is now available in Australia.
New Chief Financial Officer appointment
22 Jul 2022
Mayne Pharma Group Limited is pleased to announce that Mr Aaron Gray has been appointed as Chief Financial Officer (CFO), effective 29 August 2022.